14 March 2022 - Newsletter

Strategic partnership in transdermal systems gives drug specialist AMW better access to new markets and patient groups

As part of a strategic partnership, the German healthcare company AMW will in future focus on the development, approval and licensing of biodegradable transdermal delivery systems. The new French partner AdhexPharma is responsible for series production and lifecycle management and brings with it the best prerequisites for this. “We are pleased that our portfolio company AMW and AdhexPharma have decided on this win-win partnership and are very confident about the cooperation,” says SHS partner Manfred Ulmer-Weber.